← Leaderboards
Chien-Liang Glenn Lin
Ohio State University
$9,468,365
Attributed
$9,468,365
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2006–22$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$9,468,365 · 6
By mechanism
U01$6,771,600 · 2
R01$1,895,114 · 2
R21$801,651 · 2
Top collaborators
No co-investigators on record.
Most similar at Ohio State University
Same institution · by research overlap
- Ming You$26,875,453
- Peter G. Shields$24,078,159
- Chack Y Yu$4,824,738
- Rama K Mallampalli$45,256,042
- Kevin Robert Coombes$3,622,499
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposGlutamate TransporterAstrocytesMessenger RnaPathogenesisS DiseasePlayMediatingExtracellularGlutamatesProtein ExpressionSynapsesExcitatory Amino Acid Transporter 2Toxic EffectSafetyPreventSeriesMouse ModelSolubilityEventProtein FunctionLeadIn VitroMemory
Grant awards (17)
Development of a small-molecule that enhances tripartite synapses for Alzheimers disease$1,488,988
U01 · FY2022 · AG · contact PI
Development of a small-molecule that enhances tripartite synapses for Alzheimers disease$1,492,896
U01 · FY2021 · AG · contact PI
Development of a small-molecule that enhances tripartite synapses for Alzheimers disease$1,552,548
U01 · FY2020 · AG · contact PI
Target identification of small molecule LDN/OSU-215111$456,800
R21 · FY2020 · AG · contact PI
Development of small molecule activators of glutamate transporter EAAT2 for treatment of Alzheimer's disease$542,989
U01 · FY2019 · AG · contact PI
Development of small molecule activators of glutamate transporter EAAT2 for treatment of Alzheimer's disease$383,440
U01 · FY2019 · AG · contact PI
Development of small molecule activators of glutamate transporter EAAT2 for treatment of Alzheimer's disease$538,309
U01 · FY2018 · AG · contact PI
Development of small molecule activators of glutamate transporter EAAT2 for treatment of Alzheimer's disease$772,430
U01 · FY2017 · AG · contact PI
Translational regulation of glutamate transporter EAAT2 & therapeutic application$437,330
R01 · FY2010 · NS · contact PI
Translational regulation of glutamate transporter EAAT2 & therapeutic application$95,750
R01 · FY2010 · NS · contact PI
Translational regulation of glutamate transporter EAAT2 & therapeutic application$450,448
R01 · FY2009 · NS · contact PI
Consequence of RNA oxidation$154,238
R21 · FY2007 · AG · contact PI
Consequence of RNA oxidation$190,613
R21 · FY2006 · AG · contact PI
MECHANISMS FOR GLUTAMATE TRANSPORTER ALTERATIONS IN ALZH$217,339
R01 · FY2003 · MH
MECHANISMS FOR GLUTAMATE TRANSPORTER ALTERATIONS IN ALZH$212,034
R01 · FY2002 · MH
MECHANISMS FOR GLUTAMATE TRANSPORTER ALTERATIONS IN ALZH$239,925
R01 · FY2001 · MH
MECHANISMS FOR GLUTAMATE TRANSPORTER ALTERATIONS IN AD$242,288
R01 · FY2000 · MH